Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30259592 | 1.00 | MEP1B (0.37) | MEP1BKDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL1994314 | 0.80 | MEP1B (0.41) | MEP1BKDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL9873091 | 0.77 | KDM4E (0.43) | MEP1BKDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL3839127 | 0.77 | MEP1B (0.32) | MEP1B | |
| SCHEMBL3838297 | 0.77 | NQO1 (0.34) | ALDH1A1SMN1; SMN2 | |
| Nitrogen SCHEMBL29123071 | 0.76 | MEP1B (0.39) | MEP1BKDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL24899657 | 0.76 | KDM4E (0.31) | KDM4EALDH1A1MAPK1SMN1; SMN2MCL1 | |
| SCHEMBL3836204 | 0.75 | — | — | |
| SCHEMBL4435401 | 0.75 | MAPT (0.37) | MEP1BKDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL18620545 | 0.75 | APP (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678634-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | Haihe Biopharma Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024183793-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | 上海海和药物研究开发股份有限公司 | 2024-09-12 | — | — | WO | disclosed |
| EP-3689868-B1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20220388984-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-20210139458-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-06-07 | — | — | US | disclosed |
| EP-2099755-A2 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | Glenmark Pharmaceuticals S.A. (CH) | 2009-09-16 | — | — | EP | disclosed |
| US-20080182851-A1 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-07-31 | — | — | US | disclosed |
| WO-2008062276-A2 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139458-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | MEP1B 1863/4885KDM4E 1438/4885ALDH1A1 2301/4885 |
| US-20220388984-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | MEP1B 1863/4885KDM4E 1438/4885ALDH1A1 2301/4885 |
| US-20080182851-A1 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | SCD, SCD5, ACACA | MEP1B 2414/4885KDM4E 1815/4885ALDH1A1 578/4885 |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | MEP1B 1863/4885KDM4E 1438/4885ALDH1A1 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.